CY1115400T1 - Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων - Google Patents
Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασωνInfo
- Publication number
- CY1115400T1 CY1115400T1 CY20141100435T CY141100435T CY1115400T1 CY 1115400 T1 CY1115400 T1 CY 1115400T1 CY 20141100435 T CY20141100435 T CY 20141100435T CY 141100435 T CY141100435 T CY 141100435T CY 1115400 T1 CY1115400 T1 CY 1115400T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- disorders
- producers
- pyrazine
- suspensions
- Prior art date
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000002390 hyperplastic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0800250 | 2008-02-01 | ||
| US12303908P | 2008-04-04 | 2008-04-04 | |
| SE0801185 | 2008-05-21 | ||
| EP09706385.3A EP2252597B1 (en) | 2008-02-01 | 2009-01-28 | Pyrazine derivatives and their use as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115400T1 true CY1115400T1 (el) | 2017-01-04 |
Family
ID=40527384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100435T CY1115400T1 (el) | 2008-02-01 | 2014-06-17 | Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8436171B2 (https=) |
| EP (2) | EP2671876A3 (https=) |
| JP (2) | JP5562256B2 (https=) |
| KR (1) | KR101599082B1 (https=) |
| CN (1) | CN101970418B (https=) |
| AU (1) | AU2009209633C1 (https=) |
| BR (1) | BRPI0907453A2 (https=) |
| CA (1) | CA2713553A1 (https=) |
| CY (1) | CY1115400T1 (https=) |
| DK (1) | DK2252597T3 (https=) |
| ES (1) | ES2459297T3 (https=) |
| HR (1) | HRP20140547T1 (https=) |
| MX (1) | MX2010007973A (https=) |
| PL (1) | PL2252597T3 (https=) |
| PT (1) | PT2252597E (https=) |
| RU (1) | RU2493152C2 (https=) |
| SI (1) | SI2252597T1 (https=) |
| WO (1) | WO2009095399A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101599082B1 (ko) * | 2008-02-01 | 2016-03-02 | 어키니언 파마슈티칼스 아베 | 피라진 유도체 및 단백질 키나아제 억제제로서의 이의 용도 |
| US9109227B2 (en) | 2010-01-05 | 2015-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FLT3 receptor antagonists for the treatment or the prevention of pain disorders |
| WO2013089636A1 (en) * | 2011-12-15 | 2013-06-20 | Akinion Pharmaceuticals Ab | Processes for manufacturing of a kinase inhibitor |
| MX356102B (es) * | 2012-03-14 | 2018-05-14 | Univ Indiana Res & Tech Corp | Compuestos y métodos para tratar leucemia. |
| PT2840080T (pt) * | 2012-04-17 | 2018-02-06 | Fujifilm Corp | Composto heterocíclico que contém azoto ou sal do mesmo |
| UY34807A (es) * | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| CN105683167B (zh) | 2013-10-16 | 2018-10-23 | 富士胶片株式会社 | 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂 |
| CN107001283B (zh) | 2014-07-31 | 2021-05-25 | 国家健康与医学研究院 | Flt3受体拮抗剂 |
| WO2016027904A1 (ja) | 2014-08-22 | 2016-02-25 | 富士フイルム株式会社 | Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用 |
| CN105985322A (zh) * | 2015-03-03 | 2016-10-05 | 苏州翔实医药发展有限公司 | 氨基吡嗪化合物及其用途 |
| JP6412471B2 (ja) | 2015-07-15 | 2018-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物の製造方法およびその中間体 |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| WO2018211018A1 (en) | 2017-05-17 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 inhibitors for improving pain treatments by opioids |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| CN110483366B (zh) * | 2018-05-14 | 2022-09-16 | 中国医学科学院药物研究所 | 吲哚类化合物及其制备方法、药物组合物和用途 |
| EP3911323A4 (en) | 2019-01-18 | 2022-11-16 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| JP2022517418A (ja) * | 2019-01-18 | 2022-03-08 | ニューベイション・バイオ・インコーポレイテッド | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112574192B (zh) * | 2020-12-24 | 2021-10-01 | 烟台大学 | 氨基酸衍生联噻唑-色胺类抗癌化合物和应用 |
| KR20250075302A (ko) * | 2023-11-21 | 2025-05-28 | (주)신테카바이오 | 크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 아토피 피부염의 예방 또는 치료용 조성물 |
| KR20250075303A (ko) * | 2023-11-21 | 2025-05-28 | (주)신테카바이오 | 크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 건선의 예방 또는 치료용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (https=) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
| US20040102455A1 (en) * | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
| AUPS251502A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Protein kinase inhibitors |
| DE60317198T2 (de) * | 2002-05-23 | 2008-12-04 | Cytopia Research Pty. Ltd., Richmond | Proteinkinaseinhibitoren |
| GB2400101A (en) * | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| AU2004278382B2 (en) * | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2005058876A1 (en) | 2003-12-16 | 2005-06-30 | Gpc Biotech Ag | Pyrazine derivatives as effective compounds against infectious diseases |
| ATE458730T1 (de) | 2004-04-13 | 2010-03-15 | Icagen Inc | Polycyclische pyrazine als kaliumionenkanal- modulatoren |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| JP5252404B2 (ja) | 2006-08-16 | 2013-07-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラジン化合物、その使用及び調製方法 |
| DK2848610T3 (da) * | 2006-11-15 | 2017-11-06 | Ym Biosciences Australia Pty | Hæmmere af kinaseaktivitet |
| KR101599082B1 (ko) * | 2008-02-01 | 2016-03-02 | 어키니언 파마슈티칼스 아베 | 피라진 유도체 및 단백질 키나아제 억제제로서의 이의 용도 |
-
2009
- 2009-01-28 KR KR1020107017417A patent/KR101599082B1/ko not_active Expired - Fee Related
- 2009-01-28 AU AU2009209633A patent/AU2009209633C1/en not_active Ceased
- 2009-01-28 EP EP13182880.8A patent/EP2671876A3/en not_active Withdrawn
- 2009-01-28 DK DK09706385.3T patent/DK2252597T3/da active
- 2009-01-28 MX MX2010007973A patent/MX2010007973A/es active IP Right Grant
- 2009-01-28 PL PL09706385T patent/PL2252597T3/pl unknown
- 2009-01-28 BR BRPI0907453-8A patent/BRPI0907453A2/pt not_active Application Discontinuation
- 2009-01-28 WO PCT/EP2009/050931 patent/WO2009095399A2/en not_active Ceased
- 2009-01-28 CA CA2713553A patent/CA2713553A1/en not_active Abandoned
- 2009-01-28 JP JP2010544683A patent/JP5562256B2/ja not_active Expired - Fee Related
- 2009-01-28 US US12/865,359 patent/US8436171B2/en not_active Expired - Fee Related
- 2009-01-28 CN CN2009801038291A patent/CN101970418B/zh not_active Expired - Fee Related
- 2009-01-28 HR HRP20140547AT patent/HRP20140547T1/hr unknown
- 2009-01-28 PT PT97063853T patent/PT2252597E/pt unknown
- 2009-01-28 SI SI200930949T patent/SI2252597T1/sl unknown
- 2009-01-28 RU RU2010136653/04A patent/RU2493152C2/ru not_active IP Right Cessation
- 2009-01-28 ES ES09706385.3T patent/ES2459297T3/es active Active
- 2009-01-28 EP EP09706385.3A patent/EP2252597B1/en active Active
-
2013
- 2013-03-15 US US13/833,231 patent/US20130203774A1/en not_active Abandoned
-
2014
- 2014-04-04 JP JP2014077470A patent/JP2014148522A/ja active Pending
- 2014-06-17 CY CY20141100435T patent/CY1115400T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2252597B1 (en) | 2014-03-19 |
| RU2010136653A (ru) | 2012-03-10 |
| EP2671876A2 (en) | 2013-12-11 |
| RU2493152C2 (ru) | 2013-09-20 |
| US20130203774A1 (en) | 2013-08-08 |
| PT2252597E (pt) | 2014-04-30 |
| BRPI0907453A2 (pt) | 2015-07-14 |
| JP2014148522A (ja) | 2014-08-21 |
| US20110098310A1 (en) | 2011-04-28 |
| HRP20140547T1 (hr) | 2014-07-18 |
| WO2009095399A2 (en) | 2009-08-06 |
| US8436171B2 (en) | 2013-05-07 |
| EP2252597A2 (en) | 2010-11-24 |
| WO2009095399A3 (en) | 2009-10-01 |
| JP2011510948A (ja) | 2011-04-07 |
| MX2010007973A (es) | 2010-11-09 |
| KR20100116599A (ko) | 2010-11-01 |
| EP2671876A3 (en) | 2014-02-05 |
| JP5562256B2 (ja) | 2014-07-30 |
| SI2252597T1 (sl) | 2014-07-31 |
| DK2252597T3 (da) | 2014-04-28 |
| CN101970418B (zh) | 2013-07-03 |
| CN101970418A (zh) | 2011-02-09 |
| CA2713553A1 (en) | 2009-08-06 |
| HK1149268A1 (en) | 2011-09-30 |
| PL2252597T3 (pl) | 2014-09-30 |
| AU2009209633C1 (en) | 2014-01-23 |
| AU2009209633B2 (en) | 2013-07-18 |
| ES2459297T3 (es) | 2014-05-08 |
| AU2009209633A1 (en) | 2009-08-06 |
| KR101599082B1 (ko) | 2016-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115400T1 (el) | Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων | |
| CY1123625T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων | |
| CY1118498T1 (el) | Παραγωγα πυριδαζινονης | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| CY1121699T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| CY1113665T1 (el) | Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| CY1110044T1 (el) | Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης | |
| PT1971601E (pt) | Derivados de n4-fenil-quinazolina-4-amina e compostos relacionados como inibidores de tirosina quinases receptoras do tipo i erbb para o tratamento de doenças hiperproliferativas | |
| UA94622C2 (en) | Kinase innhibitor | |
| MX2008005398A (es) | Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer. | |
| CY1118717T1 (el) | Αναστολεις c-fms κινασης | |
| TW200519104A (en) | Quinazoline derivatives | |
| CY1118061T1 (el) | Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση | |
| IL189194A (en) | Benzimidazoles are conserved as kinase inhibitors and their use in the preparation of cancer drugs | |
| EA201201289A1 (ru) | Морфолинилхиназолины | |
| CY1111556T1 (el) | Παραγωγα 2-βενζυλοπυριδαζινονης ως αναστολεις μετ-κινασης | |
| MX2009008338A (es) | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. | |
| NZ629807A (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| CY1117461T1 (el) | Παραγωγα κιναζολινοδιονης, παρασκευη αυτων και οι θεραπευτικες εφαρμογες τους | |
| EA201100334A1 (ru) | Бициклические производные триазола для лечения опухолей | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors |